×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: covid | merck | molunpiravir | pill

Merck's COVID-19 Pill Effective Against Omicron in Lab Studies

bottle of Merck's COVID-19 pill molnupiravir
(Dreamstime)

Friday, 28 January 2022 07:14 AM

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc were authorized in the United States in December and are considered as important tools against omicron.

Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against omicron.

Merck said earlier this month its pill has a mechanism that can work against omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading omicron variant. The data evaluated the antiviral activity of molnupiravir and other COVID-19...
covid, merck, molunpiravir, pill
138
2022-14-28
Friday, 28 January 2022 07:14 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved